modelH03AA01

Diagram of H03AA01

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:LevothyroxineSodium
ATC code:H03AA01
route:oral
compartments:2
dosage:600mg
volume of distribution:10.5L
clearance:0.034L/h
other parameters in model implementation

Levothyroxine sodium is a synthetic form of the thyroid hormone thyroxine (T4), used primarily for the treatment of hypothyroidism and as replacement therapy in patients with thyroid hormone deficiency. It is an FDA-approved medication and widely used today.

Pharmacokinetics

Pharmacokinetics in healthy adult volunteers after oral administration of a single dose; both sexes, fasting condition.

References

  1. Fitch, R, et al., & Harper, D (2025). Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP-8121). Clinical and translational science 18(5) e70244–None. DOI:10.1111/cts.70244 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40348586

  2. Mateo, RCI, & Hennessey, JV (2019). Thyroxine and treatment of hypothyroidism: seven decades of experience. Endocrine 66(1) 10–17. DOI:10.1007/s12020-019-02006-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31321670

  3. Yannovits, N, et al., & Benakis, A (2006). A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers. European journal of drug metabolism and pharmacokinetics 31(2) 73–78. DOI:10.1007/BF03191122 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16898074

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)